|
所在平台: Coursera |
课程主页: https://www.coursera.org/learn/drug-commercialization
课程评论：没有评论
课程名称：药物商业化 课程概述：加州大学圣地亚哥分校斯凯格斯药学院的药物商业化课程提供了来自教职员工和行业专家的讲座。该课程在UCSD校园内录制，旨在分享行业内顶尖专家的独特经验，涵盖药物商业化的广泛领域。 课程内容包括药物经济学、市场营销策略、知识产权战略、投资组合管理、管理市场及战略联盟。此外，课程还将通过一个从初创企业到成功的案例研究，深入探讨这一过程。 课程中还将讨论上市后临床试验（Phase 4试验），这些试验在新药获得监管机构批准并上市后进行，药物在更大的患者群体中使用，从而能够开发新的治疗用途，比较不同治疗方法的效果，并确定药物在各种患者群体中的临床有效性以及识别罕见的副作用。 课程强调预营销策略应在第一阶段临床试验开始时就确立，以确保市场需求被纳入药物的整体开发。这些策略会随着临床结果在国际医学会议上的发布而不断完善，以提高医务社区对新药的认识。同时，课程还将制定定价策略和战术计划，并为销售团队进行培训，以便在产品获批后能够有效推广给医生、药剂师和护士。 该课程是系列课程的第三部分，包括：药物发现（Drug Discovery）、药物开发（Drug Development）和药物商业化（Drug Commercialization）。我们强烈建议您按顺序学习这些课程，这将帮助您更好地理解药物在实验室中如何被发现、测试及最终上市的全过程。 课程大纲： - 欢迎致辞 - 药物开发中的药物经济学，授课讲师：Jan Hirsch博士 - 知识产权战略与生物类似药，授课讲师：Williams Ettouati药剂师 - 制药和生物技术药物的市场营销，授课讲师：Williams Ettouati药剂师 - 管理市场和销售策略，授课讲师：Doral Fredericks药剂师，MBA - 学术界、制药和生物技术的战略联盟，授课讲师：Williams Ettouati药剂师 - 商业模型与投资组合管理，授课讲师：Catherine Godrecka-Bareau，CFA，默克生物类似药战略与投资组合管理总监 - 学术与行业合作“多种模型，多种结果”，授课讲师：Remi Brouard医学博士 - 从初创企业到生物技术成功的经验，授课讲师：Barry Quart药剂师
Name:Welcome!
Description:
Name:Pharmacoeconomics in Drug Development, Jan Hirsch, Ph.D.
Description:
Name:Intellectual Property Strategy & BioSimilars, Williams Ettouati, Pharm.D.
Description:
Name:Marketing Pharmaceuticals & Biotechnology Drugs, Williams Ettouati, Pharm.D.
Description:
Name:Managed Markets and Sales Strategy, Doral Fredericks, Pharm.D., MBA
Description:
Name:Strategic Alliances in Academia, Pharma and Biotech, Williams Ettouati, Pharm. D.
Description:
Name:Business Models and Portfolio Management
Description:Catherine Godrecka-Bareau, CFA Director Strategy & Portfolio Management, Biosimilars, Merck
Name:Academic Industry partnership "Various models, Various outcomes", Remi Brouard, M.D.
Description:
Name:From Start up to Success in Biotech, Barry Quart, Pharm.D.
Description:
The University of California San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences Drug Commercialization course brings you lectures from both faculty and industry experts. With this course, recorded on campus at UCSD, we seek to share our access to top people in the field who bring an unprecedented range of expertise on drug commercialization. This course will cover pharmacoeconomic, marketing strategy, intellectual property strategy, portfolio management, managed markets and strategic alliances. It will also have a lecture case study from startup to success. In addition, the course will discuss post-marketing clinical trials or Phase 4 trials. These are conducted after a new drug has been approved by the regulatory agencies and launched. In these studies, the new drug is prescribed in an everyday healthcare environment using a much larger group of patients. This enables new treatment uses for the new drug to be developed, comparisons with other treatments for the same indication to be made, and determination of the clinical effectiveness of the new drug in a wider variety of patient types, and more rare side effects, if any, may be detected . Pre-marketing strategy should be instigated as early as Phase 1 clinical trials to ensure that the market's needs are incorporated into the new drug's overall development. Later phases when clinical results are presented at international medical conferences the marketing strategy is then refined in order to develop an awareness amongst the medical community who will be prescribing the new drug. In addition to the marketing strategy, pricing strategy and a tactical plan will be developed. Promotional material, and the sales force will be trained so that when the product is approved they can promote the drug to physician, pharmacist and nurses. This course is intended as part 3 of a series: Drug Discovery (https://www.coursera.org/learn/drug-discovery), Drug Development (https://www.coursera.org/learn/drug-development) and Drug Commercialization. We would highly recommend that you take the courses in order since it will give you a better understanding on how a drug is discovered in the lab before being tested in clinical trials and then launched in the market place.
